Friday, December 8, 2023, 11:30 AM – 1:30 PM PT (2:30 PM – 4:30 PM ET)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Diffuse Large B-Cell Lymphoma (Part 2 of a 4-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting

Location
Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Michael Dickinson, MD
Hematologist
Lead of Aggressive Lymphoma
CAR-T Specialist
Peter MacCallum Cancer Centre
and Royal Melbourne Hospital
Melbourne, Australia

Grzegorz S Nowakowski, MD
Professor of Medicine and Oncology
Chair, Lymphoid Malignancy Group
Enterprise Deputy Director, Clinical Research
Mayo Clinic Comprehensive Cancer Center
Vice-Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York


Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Podcast Editor, Blood
Vancouver, British Columbia, Canada

Jason Westin, MD, MS
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Professor
Department of Lymphoma and Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.
Program Schedule — Pacific Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

MODULE 1: Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Salles

  • Key clinical and patient-related factors, such as age and performance status, comorbidities, cell of origin, molecular profile and extent of disease, in choosing initial therapy for DLBCL
  • Research establishing R-CHOP as a front-line standard for DLBCL; current role of alternative up-front chemoimmunotherapy regimens
  • Design, eligibility criteria and key efficacy and safety findings from the pivotal Phase III POLARIX trial comparing polatuzumab vedotin/R-CHP to R-CHOP for previously untreated DLBCL
  • Clinical activity observed with polatuzumab vedotin/R-CHP versus R-CHOP in various patient subsets in the POLARIX trial
  • Spectrum, frequency and severity of side effects with polatuzumab vedotin/R-CHP versus R-CHOP
  • Recent FDA approval of and patient selection for polatuzumab vedotin as a component of up-front therapy

MODULE 2: Promising Investigational Approaches to First-Line Therapy for DLBCL — Dr Nowakowski

  • Historical outcomes achieved with reduced-intensity regimens for older and/or frail patients with newly diagnosed DLBCL
  • Initial safety data from the Phase III POLAR BEAR trial comparing polatuzumab vedotin and R-mini-CHP to R-mini-CHOP for older or frail patients with previously untreated DLBCL
  • Early-phase data with first-line tafasitamab/lenalidomide and R‑CHOP from the First-MIND trial; ongoing Phase III frontMIND study
  • Clinical trial experience with and ongoing evaluation of Bruton tyrosine kinase inhibitors for newly diagnosed DLBCL
  • Results from the ZUMA-12 study evaluating axicabtagene ciloleucel (axi-cel) as first-line therapy for high-risk large B-cell lymphoma

MODULE 3: Selection and Sequencing of Novel Therapies for Relapsed/Refractory (R/R) DLBCL — Dr Sehn

  • Clinical factors in the selection and sequencing of therapy, such as prior treatment course, symptomatology and eligibility for transplant and/or chimeric antigen receptor (CAR) T-cell therapy
  • Key efficacy and safety findings with tafasitamab/lenalidomide for R/R DLBCL and current role in clinical practice
  • Available data with loncastuximab tesirine for R/R DLBCL; optimal sequencing opposite other approved regimens
  • Key findings with and current role of polatuzumab vedotin in combination with bendmustine/rituximab for R/R DLBCL
  • Optimal integration of tafasitamab/lenalidomide, loncastuximab tesirine and polatuzumab vedotin into therapy for R/R DLBCL
  • Monitoring and management of toxicities associated with novel therapies commonly employed in the relapsed-disease setting

MODULE 4: Incorporation of CAR T-Cell Therapy into the Management of R/R DLBCL — Dr Westin

  • Optimal timing for referral of patients with DLBCL for CAR T-cell therapy
  • Major findings from Phase III studies with CAR T-cell therapy as second-line treatment
  • FDA approvals of axi-cel and lisocabtagene maraleucel (liso-cel) as second-line therapy and identification of candidates for this strategy
  • Long-term efficacy and safety data with axi-cel, tisagenlecleucel and liso-cel for multiregimen-relapsed DLBCL
  • Spectrum, frequency and severity of adverse events (AEs) associated with CAR T-cell therapy for DLBCL, including cytokine release syndrome (CRS) and neurotoxicity
  • Early results with other CAR T-cell platforms for DLBCL

MODULE 5: Role of Bispecific Antibodies in the Treatment of DLBCL — Prof Dickinson

  • Mechanistic similarities and differences among bispecific antibodies targeting CD20 and CD3; implications for efficacy, tolerability and ease of use
  • Key outcomes from the pivotal Phase II NP30179 expansion study leading to the FDA approval of glofitamab for R/R DLBCL
  • Published findings with epcoritamab for R/R DLBCL in the Phase II EPCORE NHL-1 trial; recent FDA approval and ongoing Phase III evaluation
  • Recently presented data from the Phase I ELM-1 and pivotal Phase II ELM-2 studies of odronextamab for R/R DLBCL
  • Early results with other bispecific antibodies, such as mosunetuzumab and imvotamab
  • Tolerability profile of bispecific antibodies; rates and severity of CRS, neurotoxicity and other AEs
  • Available data with and ongoing assessment of bispecific antibodies with other systemic therapies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma (DLBCL).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Apply available clinical research findings in the formation of evidence-based therapeutic approaches for patients with newly diagnosed and relapsed/refractory (R/R) DLBCL.
  • Appraise published Phase III trial data documenting the benefit of CD79b-targeted therapy as a component of first-line treatment for patients with DLBCL, and consider the implications of these findings for current clinical management algorithms.
  • Assess recently presented Phase III trial data documenting the benefit of various chimeric antigen receptor T-cell platforms as second-line therapy for patients with R/R DLBCL, and consider the ramifications of these findings for routine clinical decision-making.
  • Review pivotal clinical trial findings leading to the FDA approval of other novel compounds with unique mechanisms of action for R/R DLBCL, and identify patients for whom these approaches would be appropriate.
  • Evaluate the mechanisms of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with DLBCL, and consider the current clinical role of these agents.
  • Compare and contrast the side effects associated with available and emerging therapeutic strategies for patients with DLBCL, and formulate supportive care strategies to minimize and manage these toxicities.
  • Recall ongoing clinical research evaluating novel agents and strategies for DLBCL, and appropriately counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Dickinson — Advisory Committee and Consulting Agreements: AbbVie Inc, Adicet Bio, Bristol Myers Squibb, Genmab US Inc, Gilead Sciences Inc, Kite, A Gilead Company, Nkarta Inc, Novartis, Roche Laboratories Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Novartis, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc. Prof Nowakowski — Consulting Agreements: AbbVie Inc, ADC Therapeutics, Bantam Pharmaceutical, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Daiichi Sankyo Inc, Debiopharm, F Hoffmann-La Roche Ltd, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MEI Pharma Inc, MorphoSys, Ryvu Therapeutics, Seagen Inc, Selvita, TG Therapeutics Inc, Zai Lab. Prof Salles — Advisory Committee: AbbVie Inc, Bristol Myers Squibb, Celgene Corporation, Genmab US Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Nurix Therapeutics Inc; Consulting Agreements: AbbVie Inc, atbtherapeutics, Bristol Myers Squibb, Celgene Corporation, Debiopharm, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Molecular Partners, Nordic Nanovector, Novartis, Nurix Therapeutics Inc, Orna Therapeutics; Contracted Research: Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd. Dr Sehn — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Genentech, a member of the Roche Group, Teva Oncology. Dr Westin — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Monte Rosa Therapeutics, MorphoSys, Novartis, Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Novartis, Seagen Inc; Data and Safety Monitoring Board/Committee: Century Therapeutics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, and Regeneron Pharmaceuticals Inc.

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Meeting Room
Grand Ballroom (Level 2)

Directions
Located directly across from the San Diego Convention Center, where the 2023 ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.

There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited.

NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

Thank you for your interest in our CME program. At this time online preregistration is closed for this event.. Our Onsite Registration Desk will be open at 11:00 AM PT on Friday, December 8th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Omni San Diego Hotel (675 L Street). We will accommodate onsite attendees on a first come first serve basis. Clinicians in practice will be prioritized. Onsite registration does not guarantee meal service which will be based on availability.

Omni San Diego Hotel is conveniently located 6 minutes (0.2 miles) from the San Diego Convention Center, where the 65th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

NOTICE: Registration for this event is independent of registration for the ASH Conference.

LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.